Previous Page  12 / 76 Next Page
Information
Show Menu
Previous Page 12 / 76 Next Page
Page Background

NCCN Guidelines Derivatives

| NCCN Annual Report 2016

10

2016 Highlights

Evidence-based clinical recommendations grounded in the

library of NCCN Guidelines are the foundation for a multitude of

clinical resources available to oncology stakeholders.

During 2016, NCCN substantially grew its library of available

resources with the launch of the new NCCN Imaging AUC

tm

and

publication of two new NCCN Guidelines.

Growing the Library of NCCN Guidelines

In 2016, NCCN published new Guidelines for Vulvar Cancer and

Myeloproliferative Neoplasms.

The new NCCN Guidelines for Vulvar Cancer were first made

public during the NCCN 21

st

Annual Conference: Advancing the

Standard of Cancer Care

tm

in March 2016. These Guidelines

provide recommendations on the evaluation and treatment of

squamous cell carcinoma of the vulva and include principles of

surgery, principles of radiation therapy, and systemic therapy.

The NCCN Guidelines for Myeloproliferative Neoplasms

were released in September 2016. Highly anticipated, these

Guidelines outline diagnosis, treatment, and supportive care

strategies for Myelofibrosis—a type of MPN that is the result, in

most cases, of one of three genetic mutations within the JAK2

signaling pathway.

“The management of MPNs has been variable in the past

and largely driven by review articles and individual opinions.

The NCCN Guidelines Panel for MPN hopes these inaugural

Guidelines will help leverage the evidence base in MPN care for

clear, well-informed, treatment guidelines to hopefully improve

quality of care and provide better outcomes for patients with

MPN,” said Ruben A. Mesa, MD, FACP, Mayo Clinic Cancer

Center, Chair of the NCCN Guidelines Panel for MPN.

Furthermore, 1,177 new and updated NCCN Templates

were available in 2016. NCCN Templates, derived

from the NCCN Guidelines, include chemotherapy and

immunotherapy regimens with literature support, supportive

care recommendations, monitoring parameters, and safety

instructions.

Aiding in the Value Discussion

NCCN Evidence Blocks

tm

, NCCN’s answer to the industry-

wide call for value tools in cancer care, serve as graphic

representation of five key measures that provide important

information about specific recommendations contained within

the NCCN Guidelines:

Efficacy of Regimen/Agent

Safety of Regimen/Agent

Quality of Evidence

Consistency of Evidence

Affordability of Regimen/Agent

The goal is to provide the health care provider and the patient

information to make informed choices when selecting systemic

therapies together, based upon measures related to treatment,

supporting data, and affordability.

Originally launched for Chronic Myeloid Leukemia and Multiple

Myeloma in late 2015, NCCN greatly expanded the library of

NCCN Guidelines with NCCN Evidence Blocks

tm

throughout

2016, publishing the value analyses for an additional 26 cancer

types.

>

More information about NCCN Evidence Blocks

tm

is available at

NCCN.org/evidenceblocks .

Defining the Best Care with

Limited Resources

In 2016, NCCN grew its library of available NCCN Framework

tm

to include resource-stratified treatment recommendations

for nine NCCN Guidelines. Intended for use in low- and

middle-income countries, NCCN Framework

tm

outline rational

approaches to cancer management based on the highest

achievable cancer care by applying available and affordable

resources in a logical sequence.

>

More information about NCCN Framework

tm

is available on

page 20.